Infertility/ART/IVF

Friday, November 23, 2018
Joint sessions FMM /ART/IVF

14:30-15:30 THE BEST OF RBMO 2017-2018 FLEMING
Capsule The editor’s selection of the best publications
Chairperson Bart Fauser, Netherlands
14:30-14:50 Increased miscarriage of euploid pregnancies in obese women undergoing cryopreserved embryo transfer
Kelton Tremellen, Australia
14:50-15:10 Increased insulin resistance in men with unexplained infertility
Ragaa Mansour, Egypt
15:10-15:30 Ovarian tissue cryopreservation in female-to-male transgender people: Insights into ovarian histology and physiology after prolonged androgen treatment
Chloë De Roo, Belgium
15:30-17:00 EPIGENETICS AND THE DOHaD CONCEPTS IN ART
FMM and ART session
FLEMING
Capsule Perinatal maternal conduct and conditions have profound effects on the long- term health of a newborn. What do we know? What do we think we know? What the reproductive and FMM specialists should know. This is a combined ART and FMM session with leaders in the field discussing the DOHad concept from different perspectives.
Chairpersons Lucilla Poston, UK
Nick Macklon, UK
15:30-15:55 The DOHaD concept and long-term effects
Gian Carlo Di Renzo, Italy
15:55-16:15 Epigenetics and ART
Jordana Bell, UK
16:15-16:40 Nutrition, ART and outcome
Nick Macklon, UK
16:40-17:00 Obesity, ART and outcome
Lucilla Poston, UK
17:00-18:30 FERTILITY PRESERVATION FOR SOCIAL MOTIVES
FLEMING
Capsule Freezing for social motives is like buying insurance for future fertility, and is flourishing as a new service, but is also a source of new income for IVF clinics with patients of untested fertility. The new field of ovarian tissue freezing has expanded the possibilities of postponing menopause and fertility. However, authentic discussions on cost effectiveness for  society is missing.
Chairpersons Alan DeCherney, USA
Laura Rienzi, Italy
17:00-17:45 Debate: Social freezing: What are the results of oocyte survival, pregnancy rate and obstetrics outcome?
The procedure is very effective and can ensure future fertility: Ana Cobo, Spain
Results of freezing are not as good as published:Norbert Gleicher, USA
17:45-18:05 Can we use ovarian tissue cryopreservation to delay menopause? More mothers after 50?
Jacques Donnez, Belgium
18:05-18:30 Freezing for social motives is not cost effective for society!
Zion Ben Rafael, Israel
18:30-19:30 OPENING SESSION
FLEMING
Capsule What have we learned from 40 years of the ever-evolving IVF experience? Writing the history pages of the IVF book.
Chairpersons Zion Ben Rafael, Israel
Bart Fauser, Netherlands
Rene FrydmanFrance
18:30-19:15 Nobel Prize Laureate Robert G. Edwards annual lecture.

The long and winding road to success in ART/IVF
Alan DeCherney, USA
19:15-19:30 Best Abstract Awards Ceremony
19:30-20:15 NETWORKING RECEPTION EXHIBITION AREA

Saturday, November 24, 2018
Infertility/ART/IVF

08:30-10:00 SESSION 1
PCO/PCOS
FLEMING
Capsule The definition of PCO/PCOS has changed several times during the last 4 decades. Should we change it again?  Despite our better understanding, the treatment remains a challenge.
Chairpersons Bart Fauser, Netherlands
Philllippe Bouchard, France
TBA
08:30-08:55 Defining the polycystic ovary: AMH or ultrasound?
Antonio La Marca, Italy
08:55-09:15 WHO consensus algorithm for management of anovulatory PCOS
Phillippe Bouchard, France
09:15-09:40 New insights into the PCOS
Joop Laven, Netherlands
09:40-10:00 Does Cochrane reviews show any role for metformin in the management of PCOS?
Thomas Tang, UK
10:00-10:20 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
10:20-11:50 SESSION 2
USE, ABUSE AND UNDERUSE OF PROCEDURES
FLEMING
Capsule IVF has seen many technologies that have come and gone, and were used and abused. What is the future of these technologies?
Chairpersons Joop Laven, Netherlands
Nikolaos Polyzos, Spain
10:20-10:45 ICSI: From the beginning to where we are today/ Are we abusing ICSI?
Gianpiero Palermo, USA
10:45-11:05 The end of freeze all?
Pasquale Patrizio, USA
11:05-11:30 IVM: The rise and fall and rise again of IVM?
Johan Smitz, Belgium
11:30-11:50 Achieving deliveries in primary ovarian insufficiency
Kazuhiro Kawamura, Japan
11:50-12:10 BREAK  
12:10-13:40 SESSION 3
FIBROIDS AND IVF: CAN WE REACH A CONSENSUS?
FLEMING
Capsule The current delay in family planning increases the chances of encountering fibroids and age-related infertility. Which conservative solutions do we have in hand? Despite over 250 studies, Cochran summary failed to prove that implantation and pregnancy which were affected by certain mymomas, could reversed by myomectomy. More studies are needed, but do we have a new medical solution?
Chairpersons Yacoub Khalaf, UK
Jacques Donnez, Belgium
12:10-12:40 The impact of uterine fibroids on fertility
Nikolaos Polyzos, Spain
12:40-13:10 The alternative management of uterine fibroids in infertile patients
Nicole Sänger, Germany
13:10-13:40 Medical treatment of fibroids in infertile women
Antonio La Marca, Italy
13:40-14:30 LUNCH BREAK AND POSTER VIEWING EXIBITION AREA
14:30-16:30 SESSION 4
IMPLANTATION FAILURE AND WHAT’S NEXT
FLEMING
Capsule After a few failures, physicians are expected to provide an explanation and modify the treatment. However no widely accepted definition repeated implantation failure (RIF) exist and so the reason remains mostly vague. Despite recent advances in our understanding, we do not have good solutions other than keep treating.
Chairpersons Frank Broekmans, Netherlands
Dong Zi Yang, China
Johan Smitz, Belgium
14:30-14:55 The endometrium in repeated implantation failure
Nick Macklon, UK
14:55-15:15 High-throughput single-cell RNA-seq analysis of the endometrium associated with recurrent pregnancy loss
Jan Brosens, UK
15:15-15:40 Immunology and implantation
Nathalie Ledee, France
15:40-16:00 Does RIF exist?
Edgardo Somigliana, Italy
16:00-16:30 Special COGI countercurrent lecture:
IVF outcomes over the years. Is LBR rising or declining? Why?
Norbert Gleicher, USA
16:30-16:50 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
16:50-18:20 SESSION 5
CONTROL OVARIAN STIMULATION
FLEMING
Capsule The first step in IVF is probably the most crucial and yet it varies so significantly in different centers as to prevent real comparisons. Many questions are still open despite years of studies. Why use more than 225 IU of FSH, and why not use hCG for luteal support? Should we report results of one-year outcome or keep it the usual way?
Chairpersons Norbert Gleicher, USA
Canquan Zhou¸ China
Rene Frydman, France
16:50-17:15 Why do we think more eggs is better than less eggs? Is it in the quality only?
Ben Mol, Australia
17:15-17:35 Why still use FSH dosages over 225 IU?
Frank Broekmans, Netherlands
17:35-17:55 When hCG was the luteal support drug: Will it be the come-back kid?
Claus Yding Andersen, Denmark
17:55-18:20 Which outcome should be reported in IVF? Let’s move to one-year outcome
Bart Fauser, Netherlands

Sunday, November 25, 2018
Infertility/ART/IVF

08:30-10:00 SESSION 6
ENDOMETRIOSIS ADENOMYOSIS
FLEMING
Capsule The debate continues whether mechanical infertility should be treated surgically or medically.
Chairpersons Alan DeCherney, USA
Victor Gomel, Canada
Nikolaos Polyzos, Spain
08:30-09:15 Debate: Ovarian endometrioma before infertility
Prefer IVF first: Edgardo Somigliana, Italy
Prefer surgery first:Jacques Donnez, Belgium
09:15-09:40 Artificial uterus
Mats Hellström, Sweden
09:40-10:00 Uterine adenomyosis: Can surgery help?
Leila Adamyan, Russia
10:00-10:20 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
10:20-11:50 SESSION 7
ET AND LUTEAL SUPPORT
FLEMING
Capsule Implantation is the least effective stage of IVF. The holy grail is to differentiate the many factors involved in implantation and failure. Surely ET and luteal phases support are important, but often there is little evidence with many practices never proven.
Chairpersons Edgardo SomiglianaItaly
Jacques Donnez, Belgium
Aleksandar Stefanović, Serbia
10:20-10:40 Progesterone support: Are all progesterone’s similar? Is there an upper dose for progesterone?
Avi Harlev, Israel
10:40-11:05 Adjuvant luteal support, other than progesterone. Any proofs?
Basil Tarlatzis, Greece
11:05-11:25 Why are we not all TOP-performing in embryo transfer techniques?
Mohamed Aboulghar, Egypt
11:25-11:50 MicroRNAs new generation test to explore implantation window
Samir Hamamah, France
11:50-12:10 BREAK  
12:10-13:40 SESSION 8
GENETIC TESTING OF EMBRYOS
FLEMING
Capsule Genetics testing of embryos is increasing. However, the results remain highly controversial. What has been proven to be the value of PGT, rather than what has not? What are we missing when we offer it to all?
Chairpersons Simon Fishel, UK
Pasquale Patrizio, USA
Attila Vereczkey, Hungary
12:10-12:55
Debate:
PGT for all patients 35 and older
Santiago Munne, USA
Only blastocyst transfer, no adds on (no time lapse, no PGT)
Pasquale PatrizioUSA
12:55-13:40 Debate: Mitochondrial DNA (mtDNA) can serve as a biomarker of pre-implantation embryo viability
Pros: Dagan Wells, UK
Cons: Nathan Treff, USA
13:40-14:30 LUNCH BREAK AND POSTER VIEWING EXIBITION AREA
14:30-16:30 SESSION 9
IVF: LESS IS MORE?
FLEMING
Capsule Will we do better with less eggs, less technologies, less testing?
Chairpersons Rene FrydmanFrance
Norbert Gleicher, USA
Victor Gomel, Canada
14:30-15:00 Risk of cancer in women and children after ART
Alastair Sutcliffe, UK
15:00-15:30 One and done: More or less eggs? What is the best?
Samir Hamamah, France
15:30-16:00 TBA
16:00-16:30 Special COGI-RBMO countercurrent lecture. 40 years on:
Moving towards stratifying patient treatment and removing subjectivity from IVF practice
Simon Fishel, UK
16:30-16:50 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
16:50-18:20 SESSION 10
RTD ON PROVEN AND UNPROVEN ART PROCEDURES
FLEMING
Capsule Panelist -Audience discussion
Chairpersons Zion Ben Rafael, Israel
Bart FauserNetherlands
Panelists Frank Broekmans, Netherlands
Simon Fishel, UK
Norbert Gleicher, USA
Samir Hamamah, France
Edgardo Somigliana, Italy
16:50-18:20 What evidence do we have that assisted hatching works?
What evidence do we have for the “augment” procedure?
What evidence do we have for stem cell replenishment or ovarian rejuvenation?
What evidence do we have for the value of endometrial scratching?
What evidence do we have that high dose FSH can increases success in low responders?
What evidence do we have that the “only SET policy” will not affect success?
How strong are the evidences that in vitro activation of follicles is a viable option for the future?
How strong are the evidences that DHEA / testosterone pretreatment can affect IVF results in LR?

Saturday, November 24, 2018
Infertility/ART/IVF II

08:30-10:00 SESSION 1
SPECIAL COGI WORKSHOP: THE LWC (LONDON WOMENS CLINIC) SYMPOSIUM – BUILDING THE FUTURE FAMILY:
HOW NEW TECHNOLOGIES ARE REDEFINING FAMILY PLANNING I
 WESTMINSTER
Chairperson Nick Macklon, UK
08:30-09:00 Finding a donor: Trust the clinic or do it yourself?
Joyce Harper,UK
09:00-09:30 The rise of cross border egg donation
Vanessa Vergara-Bravo, Italy
09:30-10:00 Egg donation in UK: Regulations and technology influence patient behaviour
Kamal Ahuja, UK
10:00-10:20 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
10:20-11:50 SESSION 2
SPECIAL COGI WORKSHOP:THE LWC (LONDON WOMENS CLINIC) SYMPOSIUM – BUILDING THE FUTURE FAMILY:
HOW NEW TECHNOLOGIES ARE REDEFINING FAMILY PLANNING II
WESTMINSTER
Chairperson Bart Fauser, Netherlands
10:20-10:45 Seeking perfection: Extended carrier screening in egg donation
Amelia Rodríguez-Aranda, Spain
10:40-11:05 Families created by identity-release egg donation
Susan Golombok, UK
11:05-11:30 The threats of technology to laws of disclosure: Is anonymity still realistic?
Guido Pennings, Belgium
11:30-11:50 Regulatory implications in the UK for cross border movement of frozen gametes
Nick Jones, UK
11:50-12:10 BREAK  
12:10-13:40 SESSION 3
SPECIAL COGI & ALPHA SOCIETY WORKSHOP SESSION:
ARE WE MAKING ADVANCES IN THE LABORATORY?
WESTMINSTER
Session Laboratory work
Capsule
Time lapse use is growing. What advantages does it provides? Can we improve embryo quality? 
Chairpersons
Cristina Hickman, UK
Roger Sturmey, UK
12:10-12:35 Time-Lapse: Useful algorithms or just nice videos?
Alison Campbell, UK
12:35-12:55 Can artificial intelligence help to select viable embryos?
Cristina Hickman, UK
12:55-13:20 What can be done to improve embryo culture?
Laura Rienzi, Italy
13:20-13:40 What biomarkers are worth measuring?
Roger Sturmey, UK
13:40-14:30 LUNCH BREAK AND POSTER VIEWING EXIBITION AREA
14:30-16:30 SESSION 4
SPECIAL COGI & ALPHA SOCIETY WORKSHOP SESSION: WHAT MAKES A GOOD EMBRYO?
WESTMINSTER
Session Improving embryo quality  
Capsule Can we improve embryo quality or just select the good one?
Chairpersons Laura RienziItaly
Stephen Harbottle, UK
14:30-14:50 Progress with in vitro maturation
Evelyn Telfer, UK
14:50-15:15 CRISPER editing of the human embryo
Helen O’Neill, UK
15:15-15:35 Does parental diet really matter?
Judith Eckert, UK
15:35-16:00 A design for life: How to get the most out of your laboratory
Stephen Harbottle, UK
16:00-16:30 Special COGI-RBMO countercurrent lecture:
Aneuploidy and mosaic embryos can be transferred
Siobhan Quenby, UK
16:30-16:50 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
16:50-18:20 SESSION 5
CONTROL OVARIAN STIMULATION
WESTMINSTER
Capsule Global screening is increasingly used, but do we have evidence of its cost effectiveness? Why do we need to screen all donors?
Chairpersons Joyce HarperUK
Rita Vassena, Spain
16:50-17:35 Debate: Global re-evaluation of genetic testing in-light of the most recent advancements
Evidences are still lacking:Norbert Gleicher, USA
Evidences have been achieved:Laura Rienzi, Italy
17:35-18:00 Should we fully screen all donors or only if the male is a carrier?
Rita Vassena, Spain
18:00-18:20 An update on reproductive genetics.  What does the future hold?
Joyce Harper, UK

Sunday, November 25, 2018
Infertility/ART/IVF II

08:30-10:00 SESSION 6
MOSAICISM
WESTMINSTER
Capsule One of the limitations of PGT is the interpretation of mosaicism. While it was proven that mosaic embryos can be transferred and result in normal babies, the true meaning of the high rate of mosaicism found in PGT remains controversial. In a multilateral debate, the authors will argue three different standpoints.
Chairpersons Rita Vassena, Spain
Samir Hamamah, France

08:30-08:50 Selective outcome reporting and sponsorship in randomized controlled trials in IVF and ICSI
Fulco van der Veen, Netherlands
08:50-09:35 Debate:
Mosaicism is not an obstacle for PGS to work: Santiago Munne, USA
PGS works and mosaicism is overestimated: Nathan Treff, USA
09:35-10:00 Genomic medicine for personalized IVF/ICSI cycle
Samir Hamamah, France
10:00-10:20 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
10:20-11:50 SESSION 7
JOINT COGI – ISMAAR SESSION (International Society for Mild Approaches in Assisted Reproduction)
WESTMINSTER
Capsule It is widely accepted that mild stimulation for IVF reduces health risks for women and provides better quality oocytes. This session is dedicated to describing indications and management of natural and mild stimulation IVF cycles including the role of advanced ultrasound in improving outcomes
Chairpersons Geeta Nargund, UK
Mattheos Fraidakis, Greece
10:20-10:50 The birth of the first “Test Tube Baby” in the British press
Katie Dow, UK
10:50-11:20 Natural and mild IVF – When and how to do it.
Geeta Nargund, UK
11:20-11:50 The role of advanced ultrasound in improving outcomes in natural and mild IVF
Stuart Campbell, UK
11:50-12:10 BREAK  
12:10-13:40 SESSION 8
SPECIAL WORKSHOP – HISTORY OF IVF: PART I
WESTMINSTER
Capsule
This session is based on the book “The History of IVF”, to be published later this year in celebration of the 40th anniversary of IVF. The authors, all pioneers in their respective countries, will present their experience and discuss the development of IVF from its beginning to a huge interdisciplinary medical field which helps millions of patients, affecting many lives and even spilling over to the assistance of endangered species. Read the book for more and to see the topics and speakers’ bios.
Chairpersons
Gab Kovacs, Australia
Peter Brinsden, UK
12:10-12:30 The early American experience
Alan DeCherney, USA
12:30-12:45 The track to assisted reproduction: Animal to human IVF
Jacques Cohen, USA
12:45-13:05 The early days in the UK: Steptoe, Edwards, Purdy and Bourn Hall
Peter Brinsden, UK
13:05-13:20 The contributions from “down under”
Gab Kovacs, Australia
13:20-13:40 Developments in Europe
Basil Tarlatzis, Greece
Klaus Diedrich, Germany
13:40-14:30 LUNCH BREAK AND POSTER VIEWING EXIBITION AREA
14:30-16:30 SESSION 9
SPECIAL WORKSHOP – HISTORY OF IVF: PART II
WESTMINSTER
Capsule
Based on the book “The History of IVF”, Part II
Chairpersons
Jacques Cohen, USA
14:30-15:00 Development of IVF in India
Rina Agrawal, UK
15:00-15:30 The development of ovarian stimulation protocols for IVF
Colin Howles, Switzerland
15:30-16:00 Research on ART families: An historical perspective
Susan Golombok, UK
16:00-16:30 The commercialization of IVF in the UK
Tony Rutherford, UK
16:30-16:50 COFFEE BREAK AND POSTER VIEWING EXIBITION AREA
IVF/ART/Infertility sessions continue in Fleming

*The scientific program is subject to change.